ScinoPharm Taiwan Ltd
TWSE:1789
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
Castro Model Ltd
TASE:CAST
|
IL |
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| TW |
|
ScinoPharm Taiwan Ltd
TWSE:1789
|
16.4B TWD |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
869B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
588.6B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
227.8B GBP |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
297.7B USD |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
229.9B CHF |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
237.1B USD |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
159.7B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1T DKK |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
122.1B USD |
Loading...
|
Market Distribution
| Min | -197.7% |
| 30th Percentile | 13.7% |
| Median | 22.1% |
| 70th Percentile | 31.4% |
| Max | 400.8% |
Other Profitability Ratios
ScinoPharm Taiwan Ltd
Glance View
ScinoPharm Taiwan Ltd. engages in the research, development, manufacturing, and sales of active pharmaceutical ingredients and injections. The company is headquartered in Tainan, Tainan. The company went IPO on 2010-10-29. The main products include active pharmaceutical ingredients, protein drugs, oligonucleotides, peptides, injection preparations, new small molecule drugs and other chemical raw materials. The firm is also engaged in the provision of consulting and biotechnology services for related products, the international trading of products, as well as the provision of customized full-process services such as chemical molecular component synthesis, process development and commercial mass production. The firm operates within the domestic market and to overseas markets, including the Americas, Europe, Australia and Asia.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for ScinoPharm Taiwan Ltd is 34.7%, which is below its 3-year median of 37.4%.
Over the last 3 years, ScinoPharm Taiwan Ltd’s Gross Margin has decreased from 38.3% to 34.7%. During this period, it reached a low of 34.7% on Jan 1, 2026 and a high of 39.5% on Sep 30, 2024.
